APGE
HealthcareApogee Therapeutics, Inc. · Biotechnology · $5B
What is Apogee Therapeutics, Inc.?
Apogee Therapeutics is a clinical-stage biotechnology company focused on developing extended half-life biologics for inflammatory and immunology conditions. Founded in 2022 and headquartered in Waltham, Massachusetts, the company is building a pipeline centered on atopic dermatitis and chronic obstructive pulmonary disease.
Apogee Therapeutics develops subcutaneous monoclonal antibodies engineered with extended half-lives, meaning patients would need less frequent dosing than existing treatments. Its lead programs target atopic dermatitis — a chronic inflammatory skin condition — and chronic obstructive pulmonary disease. The company's approach aims to improve on current biologics by offering longer-acting alternatives. As a pre-revenue clinical-stage company, Apogee funds its operations through capital raises rather than product sales.
Apogee Therapeutics was founded in 2022 and is headquartered in Waltham, Massachusetts.
- APG777 — extended half-life mAb for atopic dermatitis
- APG808 — extended half-life mAb for COPD
- APG990 — earlier-stage mAb program for atopic dermatitis
- APG222 — extended half-life antibody for atopic dermatitis
Is APGE a Good Stock to Buy?
UQS Score rates APGE as Poor overall, reflecting the early-stage nature and current risk profile of the business.
Among the five pillars, Risk stands out as the relative bright spot — suggesting the company carries a manageable balance sheet position compared to many clinical-stage peers. This is not uncommon for well-funded biotechs that have recently raised capital.
Quality, Moat, and Growth all register as Weak, which is typical for a pre-revenue company with no approved products, no durable competitive advantages yet established, and a pipeline still in clinical development. Valuation is rated Elevated, meaning the current market price reflects significant future expectations.
See the full pillar breakdown and underlying financial metrics by signing up for a UQS Pro account. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does APGE pay dividends?
No — Apogee Therapeutics, Inc. does not currently pay a dividend.
Apogee Therapeutics does not pay a dividend. As a clinical-stage biotech with no approved products or commercial revenue, the company directs all available capital toward research, clinical trials, and pipeline development. Income-focused investors should be aware that dividend distributions are not part of the current business model.
When does APGE report earnings?
Apogee Therapeutics reports financial results on a quarterly cadence, consistent with US-listed public companies.
As a pre-revenue company, quarterly reports focus primarily on cash runway, operating expenses, and clinical pipeline updates rather than revenue or profitability metrics. Investors typically watch for trial progress and capital position disclosures.
For the most recent quarter's results and pipeline updates, visit Apogee Therapeutics' investor relations page directly.
APGE Price History
+324.6% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in Apogee Therapeutics, Inc.?
Based on Apogee Therapeutics, Inc.'s historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
APGE Long-term Outlook
Apogee's fundamental outlook is shaped by its clinical-stage status. The Growth pillar is rated Weak, reflecting the absence of commercial revenue and the long timelines typical of drug development. The Risk pillar rating of Good provides some reassurance around near-term financial stability, but the path to value creation depends heavily on clinical trial outcomes. Elevated Valuation suggests the market has already priced in meaningful pipeline success, leaving limited margin for setbacks.
Growth drivers
- Positive clinical data readouts for APG777 or APG808 could unlock significant value
- Large addressable markets in atopic dermatitis and COPD with unmet patient needs
- Extended half-life platform differentiation may attract partnership or licensing interest
Key risks
- Clinical trial failure or delays would materially impact the investment case
- Elevated Valuation leaves little room for disappointment relative to pipeline expectations
- Ongoing cash burn requires continued access to capital markets
APGE vs Peers
Apogee Therapeutics operates in a competitive immunology and respiratory biologics landscape alongside several specialty biopharma companies.
Apellis focuses on complement system-targeted therapies and has approved commercial products, giving it a more established revenue base than Apogee.
Mirum targets rare liver diseases and has reached commercialization, differentiating it from Apogee's earlier-stage inflammatory pipeline.
Corcept is a profitable, commercial-stage company built around cortisol modulation, representing a more mature business model compared to Apogee's development-stage profile.
Frequently Asked Questions
What does Apogee Therapeutics do?
Apogee Therapeutics is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for inflammatory conditions. Its primary focus areas are atopic dermatitis and chronic obstructive pulmonary disease. The company has no approved products yet and is advancing multiple candidates through clinical trials.
Does APGE pay dividends?
No, APGE does not pay a dividend. Apogee Therapeutics is a pre-revenue clinical-stage company that reinvests all available capital into its pipeline and operations. Dividend payments are not part of the current business model.
When does APGE report earnings?
Apogee Therapeutics reports on a quarterly cadence, as is standard for US-listed public companies. For the most current earnings schedule and recent results, check the investor relations section of the company's official website.
Is APGE a good stock to buy?
UQS Score rates APGE as Poor overall. The rating reflects weak Quality, Moat, and Growth scores typical of a pre-revenue biotech, alongside an Elevated Valuation. The Risk pillar is the relative strength. Whether APGE fits your portfolio depends on your risk tolerance and investment horizon. View the full breakdown on UQS Pro.
Is APGE overvalued?
UQS Score assigns an Elevated Valuation label to APGE. This suggests the current market price embeds significant expectations for future clinical and commercial success. For a company with no approved products, that premium carries meaningful execution risk if pipeline milestones are delayed or missed.
How does APGE compare to its competitors?
Compared to peers like Corcept Therapeutics and Mirum Pharmaceuticals — both of which have commercial products — Apogee is at an earlier stage with no revenue. Apellis Pharmaceuticals also has approved therapies. Apogee's differentiation lies in its extended half-life antibody platform, though that advantage remains unproven in the market.
What is APGE's market cap bracket?
Apogee Therapeutics is classified as a mid-cap company. This places it in a range that typically attracts both institutional and retail investor attention, though mid-cap clinical-stage biotechs can carry significant volatility tied to trial outcomes.
Who founded Apogee Therapeutics?
Apogee Therapeutics was founded in 2022. For detailed information on the founding team and leadership, the company's official website and SEC filings provide publicly available biographical information on its executives and board.
Is APGE a long-term quality investment?
From a long-term quality perspective, UQS Score currently rates APGE as Poor, with Weak scores across Quality, Moat, and Growth pillars. Long-term quality indicators are not yet established for a pre-revenue company. The investment case rests on clinical pipeline execution over time rather than current fundamental strength.
What is the main competitive advantage of Apogee Therapeutics?
Apogee's core technological approach centers on engineering antibodies with extended half-lives, which could allow for less frequent dosing compared to existing biologics. If validated in trials, this could be a meaningful differentiator in atopic dermatitis and COPD markets. However, the Moat pillar is currently rated Weak, reflecting the unproven nature of this advantage.
What sector does APGE belong to?
APGE belongs to the Healthcare sector, specifically within biotechnology. The company is focused on immunology and inflammatory disease, areas that have seen significant drug development activity and commercial interest from larger pharmaceutical companies.
Is APGE a growth stock or value stock?
Based on UQS pillar labels, APGE carries a Weak Growth rating and an Elevated Valuation — an unusual combination that reflects the speculative nature of clinical-stage biotech investing. It does not fit neatly into either category in the traditional sense.
Unlock Full APGE Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓View the complete five-pillar UQS Score breakdown
- ✓Access underlying financial metrics and trend data
- ✓Compare APGE against sector peers side by side
- ✓Track Quality, Risk, and Valuation changes over time
- ✓Get the full analyst-style view available to Pro members
Pro Analysis
APGE — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 12, 2026 | 11.9 | 0.0 | 11.0 | 0.0 | 61.3 | 0.0 | -1.5 |
| Apr 2, 2026 | 13.4 | 0.0 | 11.0 | 0.0 | 71.2 | 0.0 | — |
APGE — Pillar Breakdown
Quality
— 0.0/100 (25%)Apogee Therapeutics, Inc. currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Free cash flow relative to market value.
Growth
— 0.0/100 (20%)Apogee Therapeutics, Inc. faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 61.3/100 (15%)Apogee Therapeutics, Inc. maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)Apogee Therapeutics, Inc. appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 11/100 (25%)Apogee Therapeutics, Inc. operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for APGE.
Score Composition
Financial Data
More Stock Analysis
How is the APGE UQS Score Calculated?
The UQS (Unified Quality Score) for Apogee Therapeutics, Inc. is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses Apogee Therapeutics, Inc.'s competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether Apogee Therapeutics, Inc. is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.